Ascletis and Alphamab sign licensing deal for anti-PD-L1 to treat hepatitis B and other viral diseases

Image: Ascletis and Alphamab have entered into licensing agreement for anti-PD-L1 to treat hepatitis B and other viral diseases. Photo: courtesy of renjith Krishnan / FreeDigitalPhotos.net.